The Women’s Tennis Association has entered into a partnership with noninvasive monitoring technologies company Masimo.
As part of the agreement, the length of which was not disclosed, the WTA’s Sport Sciences and Medicine (SS&M) team will use Masimo’s MightySat product, a fingertip oximeter designed for general wellness and health applications across sports, fitness and relaxation management.
MightySat provides noninvasive measurements of oxygen saturation, pulse rate, perfusion index, PVi and respiration rate based on the plethysmographic wafeform.
The SS&M team’s primary healthcare providers will use MightySat at WTA tournament events to support the health, wellness and fitness of players.
Joe Kiani, founder and chief executive of Masimo, said: “We have been encouraged by the feedback we have received from elite athletes and trainers about how MightySat helps them improve their health and performance.
“For example, they use Masimo’s unique accuracy to decide on how hard to train. We are excited to work with the WTA to help them use Masimo’s breakthrough noninvasive technologies to make a meaningful difference in women’s tennis. We have long been big fans of the sport and are excited to help these peak performing athletes reach even greater heights.”